Medicare obesity drug coverage has become a hot topic as the Centers for Medicare and Medicaid Services (CMS) recently declined to implement a proposal from the Biden Administration that could have expanded coverage for weight-loss drugs such as Wegovy and Zepbound.This decision has significant implications for beneficiaries, as these medications offer vital treatments for obesity, a condition that affects millions of Americans.